About Maximum Fair Pricing

What is Maximum Fair Pricing?

Like many states, Maryland is seeking to keep prescription drugs affordable. It’s a laudable goal; but enacting the wrong policies won’t help Maryland patients and could harm Maryland’s life sciences ecosystem.

For example, Maryland lawmakers are working to cap certain prescription medication prices by matching the drug price to Medicare’s Maximum Fair Price (MFP). Established under the Inflation Reduction Act, Medicare’s Drug Price Negotiation Program authorizes the federal government to negotiate prices for certain prescription drugs covered by Medicare. These negotiated prices are known as Maximum Fair Prices (MFPs).

Maryland now wants its Prescription Drug Affordability Board (PDAB) to use MFP’s price limits as the Upper Payment Limit (UPL) on 20 prescription medications in state health insurance plans.

This plan puts patient access to medications at risk while doing nothing to lower patient costs at the pharmacy counter. Here’s why.

MFP Could Limit Patient Access to Prescriptions

Using MFP to set UPLs will limit state reimbursements to pharmacies and other providers. In response, insurers or Pharmacy Benefit Managers (PBMs) could end up removing certain medications from preferred formularies, moving them to tiers with higher patient cost-sharing, or increasing pressure to substitute medications prescribed by a patient’s physician.

For patients whose conditions are well-controlled by a specific medication, being forced to switch drugs for insurance rather than medical reasons can disrupt their treatment and potentially risk health outcomes. These changes also undermine treatment decisions patients make with their physicians.

Medicare’s MFP Does Not Work at the State Level

Medicare’s MFP is unique. The federal government is the largest purchaser of prescription drugs in the U.S. It has the statutory authority and budgetary leverage to dictate prices and require manufacturer participation. 

States have no such authority. Their ability to set prices, regulate markets, or require participation is fragmented. Manufacturers can decline to participate in a price capping plan without exiting the national market. 

In short, tying Maryland UPLs to federal MFP prices only sets a limit on the state’s reimbursements to pharmacies and other providers. It does not lower patient out-of-pocket costs, and jeopardizes patient access to the medications they rely on. 

As the Rare Access Action Project explains, when removed from Medicare’s statutory framework, MFP functions as a reimbursement ceiling with the same access consequences as any other Upper Payment Limit (UPL).

Real savings starts with patients – not government boards. The MFP simply doesn’t lower patient costs at the pharmacy counter.

Government Price-Setting Risks Maryland’s Life Sciences Leadership

Maryland’s biopharmaceutical sector supports more than 112,000 jobs and $37.2 billion in economic output. Direct biopharmaceutical jobs average $167,457 in annual compensation—more than twice the average Maryland wage. 

While innovators and scientists are working hard to increase the state’s competitiveness, Maryland’s pursuit of government price-controls is putting the state’s future as a life sciences leader at risk.

Life sciences companies making decisions about where to locate research, manufacturing, and commercialization operations evaluate not just talent and infrastructure, but also regulatory risk. Policies that may alter reimbursement structures or limit market viability can have a chilling effect on investment particularly for early-stage and mid-sized firms that drive much of Maryland’s innovation economy.